Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
46%
SARS Coronavirus
30%
Respiratory Tract Infection
26%
Hydroxychloroquine
26%
Disease
25%
Randomized Controlled Trial
23%
COVID-19 Vaccine
17%
Lopinavir
17%
Clinical Trial
16%
Adverse Event
15%
Lopinavir Plus Ritonavir
15%
Coronavirinae
14%
Remdesivir
13%
Pharmacovigilance
13%
Levodopa-Induced Dyskinesia
13%
Xanthine
13%
Glioblastoma
13%
Respiratory Tract Disease
13%
Interferon
13%
Comorbidity
13%
Antivirus Agent
13%
Messenger RNA
13%
Observational Study
13%
Overall Survival
8%
Progression Free Survival
8%
Drug Screening
8%
Cardiovascular Disease
7%
Medicine and Dentistry
Parkinson's Disease
40%
Respiratory Tract Infection
26%
COVID-19
26%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Booster Dose
17%
COVID-19 Vaccine
16%
Respiratory Disease
13%
Gut Microbiome
13%
Mild Cognitive Impairment
13%
microRNA
13%
Progressive Supranuclear Palsy
13%
Observational Study
13%
Cardiovascular System
13%
Omicron Coronavirus Variant
13%
Comorbidity
13%
Metabolomics
13%
Messenger RNA
11%
Disease
7%
Cardiovascular Disease
7%
Neuroscience
Parkinson's Disease
100%
L-DOPA
26%
Dyskinesia
26%
Mild Cognitive Impairment
26%
Progressive Supranuclear Palsy
13%
MicroRNA
13%
Comorbidity
13%